Program for Assessment of Capecitabine (Xeloda) Based First-line Therapies in Metastatic Colorectal Cancer (AXEL Study)
Phase of Trial: Phase IV
Latest Information Update: 25 Mar 2017
Price : $35 *
At a glance
- Drugs Capecitabine (Primary) ; Bevacizumab
- Indications Colorectal cancer
- Focus Therapeutic Use
- Acronyms AXEL
- Sponsors Roche
- 09 Mar 2015 Status changed from active, no longer recruiting to completed, according to ClinicalTrials.gov record.
- 14 Jul 2014 Planned End Date changed from 1 Mar 2014 to 1 Dec 2014 as reported by ClinicalTrials.gov.
- 14 Jul 2014 Planned primary completion date changed from 1 Mar 2014 to 1 Dec 2014 as reported by ClinicalTrials.gov.